BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Japan

Pfizer and Astellas Gain Landmark FDA Approval for PADCEV and Keytruda in Cisplatin Ineligible Muscle Invasive Bladder Cancer

PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve survival over current standard of ca...

November 24, 2025 | News

Thermo Fisher FDA Clearance Expands Precision Pathway for HER2 Driven Lung Cancer Treatment

Test will serve as a companion diagnostic for Bayer’s HYRNUO™ (sevabertinib) to identify patients with NSCLC eligible for HER2-targeted therapy...

November 21, 2025 | News

10x Genomics And ASTRA Consortium Launch Asia Pacific Pan Cancer Spatial Atlas To Advance Precision Oncology

Initiative led by researchers in Australia and Japan aims to map cancer and immune interactions to advance precision oncology across the region 10x Genomi...

November 19, 2025 | News

Debiopharm Transitions JCA Mauvernay Award Into New IDEAL Japan Programme To Drive Next Generation Oncology Research

After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support ...

November 19, 2025 | News

Ono Opens New Zug Office to Support Strategic Expansion Across the EMEA Region

Ono Pharmaceutical Co., Ltd. announced the opening of a new 733-square-meter office in Zug, Switzerland, to accommodate the company’s growth in Europ...

November 18, 2025 | News

Lundbeck Moves Closer to Asian Launch of Vyepti with New Drug Application Accepted in Japan

Lundbeck's new drug application (NDA) for Vyepti® (eptinezumab) accepted by Japan's Ministry of Health, Labor and Welfare (MHLW), mark...

November 17, 2025 | News

PRISM BioLab Reaches Initial Milestone in Joint Oncology Research under Agreement with Ono Pharmaceutical

PRISM BioLab, Co. Ltd. ("PRISM") announces that , PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka; President and COO: Toichi Takino; hereinafte...

November 17, 2025 | News

Project ACTIVE Two Point Zero Launches to Strengthen Cervical Cancer Care Across Southeast Asia

A major step forward in regional collaboration for cancer care was announced today with the launch of Project ACTIVE 2.0 (Advancing Cervical Cancer Tr...

November 14, 2025 | News

BostonGene and Kyoto University Launch AI Collaboration to Advance Precision Treatment for Esophageal Cancer

-BostonGene, developer of the leading AI foundation model for cancer and the immune system, and Kyoto University, a research institution known for its...

November 14, 2025 | News

Teijin and BioVaram Form Strategic Alliance To Advance Regenerative Medicine and Implantable Medical Technologies Across Japan and India

Teijin Limited and BioVaram, the brand name of the UR Advanced Therapeutics Pvt Ltd. (URAT), announced today ...

November 13, 2025 | News

TOPPAN Expands Sustainable Packaging Capabilities with Hybrid BOPP–BOPE Film Manufacturing Line in India

TOPPAN Inc. (TOPPAN), a TOPPAN Group company and wholly owned subsidiary of TOPPAN Holdings Inc. (TYO: 7911) (TOPPAN Holdings), and its India-based subsidi...

November 11, 2025 | News

Takeda’s Mezagitamab Shows Sustained Kidney Function and Proteinuria Reduction Through 18-Month Follow-Up in IgA Nephropathy

Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 ...

November 10, 2025 | News

NEXT Oncology Expands to Japan Through Partnership with Kansai Medical University

With continued global expansion, NEXT Oncology is one of the world’s largest Phase I Cancer Trial organizations. NEXT Oncology, an Avac...

November 07, 2025 | News

Asahi Kasei’s Nefecon Included in KDIGO 2025 Guideline for IgA Nephropathy Management

Asahi Kasei, a global provider of healthcare and pharmaceutical solutions, announced that Nefecon (marketed in the United States as TARPEYO® (budesonid...

November 06, 2025 | News

Stay Connected